Recent studies show that proteinase-activated receptor-2 (PAR 2 ) contributes to the development of inflammatory responses. However, investigations into the precise role of PAR 2 activation in the anti-microbial defence of human leucocytes are just beginning. We therefore evaluated the contribution of PAR 2 to the anti-microbial response of isolated human innate immune cells. We found that PAR 2 agonist, acting alone, enhances phagocytosis of Staphylococcus aureus and killing of Escherichia coli by human leucocytes, and that the magnitude of the effect is similar to that of interferon-c (IFN-c) . However, co-application of PAR 2 -cAP and IFN-c did not enhance the phagocytic and bacteria-killing activity of leucocytes beyond that triggered by either agonist alone. On the other hand, IFN-c enhances PAR 2 agonist-induced monocyte chemoattractant protein 1 (MCP-1) secretion by human neutrophils and monocytes. Furthermore, phosphoinositide-3 kinase and janus kinase molecules are involved in the synergistic effect of PAR 2 agonist and IFN-c on MCP-1 secretion. Our findings suggest a potentially protective role of PAR 2 agonists in the antimicrobial defence established by human monocytes and neutrophils.
Introduction
Proteinase-activated receptor-2 (PAR 2 ) plays a role in the development of allergic diseases of the skin 1 and in certain inflammatory disorders. 2 The impact of PAR 2 activation on inflammation can be pro-or anti-inflammatory, depending on the stage of disease and the primary cell type involved in disease progression. 2 During receptor activation, serine protease cleavage of PAR 2 unmasks the N-terminal sequence of the 'tethered ligand'. This unmasked sequence further serves as a receptor activator. 3 The PAR 2 is activated by trypsin and tryptase, and also by proteases derived from immune cells and pathogens. 4 However, serine proteases cause PAR-dependent as well as PAR-independent effects. 5, 6 As a result, specific synthetic activating peptides are important probes for investigating the role of PAR activation in different processes.
Interferon-c (IFN-c) is well-known as a mediator that has a wide range of anti-viral, anti-bacterial and antitumour or immunomodulatory activities. 7 We recently demonstrated in vitro that PAR 2 activation on human monocytes enhances the suppressive effects of IFN-c on influenza A virus replication. 8 Moreover, in vivo studies have shown that a protective role of PAR 2 against influenza infection is also mediated by an IFN-c-dependent mechanism. 9 These studies revealed interplay between PAR 2 activation and IFN-c during the anti-viral response and raise the intriguing question of whether PAR 2 activation also contributes to anti-bacterial and immunomodulatory effects triggered by IFN-c in monocytes and neutrophils.
Human neutrophils and monocytes are not only 'professional' phagocytes, they are cells that, when activated, secrete different chemokines and cytokines. Stimulation of PAR 2 agonist affects chemokine [IFN-inducible protein-10, interleukin-8 (IL-8)] and cytokine (IL-1b, IL-6) secretion by human neutrophils and monocytes. 8, 10 Among the chemokines secreted by neutrophils there is a molecule that appears to link neutrophils and monocytes during the time-delayed immune response to local infection. Monocyte chemoattractant protein-1 (MCP-1) is an essential mediator for monocyte and macrophage recruitment towards the site of infection. 11, 12 Neutrophils are a source of MCP-1 in time-delayed responses, 13 and so may attract monocytes and macrophages. However, MCP-1 is not only a chemotactic molecule for monocytes and macrophages, it also enhances the engulfment of apoptotic neutrophils (efferocytosis), thereby helping to resolve acute inflammation. 14 In addition, MCP-1 is involved in fibroblast activation and influences collagen production, which makes MCP-1 an important participant in initial events during systemic scleroderma and skin fibrosis. 15 Interferon-c is known to increase the secretion of MCP-1 by human neutrophils 48 hr after stimulation. 13 However, whether PAR 2 agonists enhance MCP-1 release or influence the IFN-c-induced secretion of MCP-1 by human neutrophils has received little study.
We therefore evaluated the contribution of PAR 2 to the anti-microbial response of isolated human innate immune cells. We investigated whether PAR 2 agonist acting alone affects the phagocytic and bactericidal activity of human neutrophils and monocytes. We also investigated whether IFN-c enhances the effect of PAR 2 agonist on the MCP-1 release by human neutrophils and monocytes, and examined the intracellular signalling molecules involved in the effects of PAR 2 agonist on MCP-1 secretion.
Materials and methods

Materials
Human recombinant IFN-c was purchased from TebuBio (Offenbach, Germany). Lipopolysaccharide (LPS) from Escherichia coli 055:B5 was purchased from Sigma (Munich, Germany; cat.#L2880). Human PAR 2 activating peptide with the sequence trans-cinnamoyl-LIGRLO-NH 2 (cAP) and reverse peptide with sequence trans-cinnamoyl-OLRGIL-NH 2 (cRP) (Peptide Synthesis Facility, University of Calgary, Canada, Director: Dr Denis McMaster; the web page: http://www.ucalgary.ca/peptides). 8, 10 Fluoresceinconjugated killed Staphylococcus aureus was purchased from Molecular Probes (Karlsruhe, Germany). The E. coli strain JM109 was obtained from Promega (Mannheim, Germany). Cell culture reagents were purchased from BioWhittaker (Aachen, Germany), PAA Laboratories (Coelbe, Germany) and Gibco-Life Technologies (Karlsruhe, Germany). Cell-permeable inhibitors of intracellular signalling molecules [SB203580, rottlerin, LY 294002 and janus kinase (JAK) inhibitor I pyridone 6] were purchased from Calbiochem (Nottingham, UK).
Cell culture and isolation of human neutrophils and monocytes
Buffy-coats with blood cells for in vitro experiments with human neutrophils and monocytes were obtained from healthy adult volunteers via the German Red Cross (Deutsches Rotes Kreuz, Münster, Germany). Neutrophils were isolated by Biocoll (Biochrom, Berlin, Germany) density gradient centrifugation followed by a hypotonic shock procedure. 10, 16 Peripheral blood monocytes were isolated by leukapheresis as previously described. 17 Isolated human monocytes were cultivated in Teflon bags in McCoy's medium (Biochrom) supplemented with 15% fetal calf serum (FCS), 2 mM L-glutamine and 1% nonessential amino acids. Monocytes were allowed to rest for 24 hr before stimulation. Isolated neutrophils were cultured in RPMI-1640 medium supplemented with 0Á9% FCS, 2 mM L-glutamine and 1% non-essential amino acids and allowed to recover for 2 hr before stimulation. The following concentrations of reagents were used for stimulation during experiments: LPS 100 ng/ml; IFN-c 10 or 100 ng/ml; PAR 2 -cAP 1 · 10
M. The corresponding reverse peptide with the reverse-sequence (PAR 2 -cRP) was used at a concentration of 1 · 10
M and served as a negative control.
Bacterial killing assay
Bacterial killing assay using E. coli (strain JM109) was performed as described previously 18, 19 with modifications. In brief, E. coli bacteria were cultured into Luria broth medium overnight at 37°. Isolated uninfected human neutrophils were pre-stimulated with 10
M PAR 2 -cAP and/or IFN-c (100 ng/ml) for 2 hr (37°, 5% CO 2 ). Unstimulated neutrophils were used as control samples. After 2 hr incubation of neutrophils with stimuli, the cell culture medium (RPMI-1640 with 0Á9% FCS, 2 mM L-glutamine and 1% non-essential amino acids) with stimuli was removed and cells were washed. Human neutrophils (2 · 10 6 cells) were resuspended in 200 ll RPMI-1640 containing 2 mM L-glutamine, 1% non-essential amino acids, 0Á2% BSA, 0Á01% CaCl 2 and 0Á01% MgCl 2 (this medium was designated the 'assay medium'). Collected and washed bacteria (40 · 10 6 cells) were opsonized for 15 min at 37°. For opsonization, bacteria were incubated in the assay medium containing 5% human serum from the same donor from whom the neutrophils were obtained. After opsonization, bacteria were washed. Neutrophils and opsonized bacteria were co-incubated in assay medium in the absence (for unstimulated control samples) or presence of stimuli (10
M PAR 2 -cAP and/or 100 ng/ml IFN-c) for 1 hr at 37°on a shaker. Neutrophils were removed from samples by hypotonic lysis (for this purpose sterile water was added to samples). A series of dilutions were prepared from the remaining bacteria. Bacteria were cultured on Luria broth agar plates without antibiotic at 37°overnight. Colonies were counted the next day.
Phagocytosis assay with killed S. aureus
The phagocytosis assay was performed as described previously. 19, 20 In brief, FITC-conjugated killed S. aureus (Invitrogen, Darmstadt, Germany) was used for assay. The bacteria were opsonized before the assay. For this purpose, bacteria were incubated with 5% serum (from the same donor from whom neutrophils were isolated) for 25 min at 37°. Non-infected neutrophils were pre-stimulated with PAR 2 -cAP 10 M and/or IFN-c 100 ng/ml for 2 hr at 37°and 5% CO 2 . Neutrophils and opsonized bacteria were co-incubated at 1 : 20 ratio (neutrophils : S. aureus). During co-incubation of bacteria and neutrophils, PAR 2 -cAP 10
M and/or IFN-c 100 ng/ml were applied in the concentrations indicated above. Co-incubation took place in assay medium on a shaker for 30 min at 37°. The phagocytosis assay was stopped by the addition of ice-cold PBS containing 0Á5 mM EDTA (500 ll PBS to 1 ml of sample medium). Samples were then centrifuged at 169 g and neutrophil pellets were resuspended in ice-cold PBS containing 0Á9% FCS and 2 mM EDTA. Trypan blue quench, which helps to discriminate adherent and ingested bacteria, was performed as described previously. 21 The efficacy of phagocytosis was estimated using flow cytometry (FACS analysis). Measurements were performed for the next 15 min and all samples were kept on ice during measurements. At least 30 000 cells were analysed with the FACSCALIBUR and CELL QUEST PRO Software (Becton Dickinson, Heidelberg, Germany).
Phagocytosis assay with live S. aureus
Bacteria. The S. aureus (SH1000) was kindly provided by Dr C. Eiff 22 and S. aureus was grown for 18 hr in Mueller-Hinton bouillon at 37°. Bacterial density was measured spectrophotometrically at 540 nm, after two PBS washings. The number of bacterial cells was calculated using a previously determined standard curve (based on the counts of colony-forming units). Finally, the concentration of bacteria in PBS was adjusted to 5 · 10 8 cells/ml. For the purpose of the quantitative analysis of phagocytosis by flow cytometry, S. aureus was incubated in PBS containing 0Á1% FITC (Sigma Aldrich, Munich, Germany) for 1 hr at 37°. After being labelled, bacteria were washed three times before incubation with pre-treated leucocytes.
Assay. During pre-treatment, human monocytes or neutrophils (1 · 10 6 cells) were cultured in medium either without stimuli ('control') or containing the following stimuli: 100 ng/ml LPS; 1 · 10
M PAR 2 -cAP, 10 ng/ml or 100 ng/ml of IFN-c. Monocytes or neutrophils were pre-treated for 2 hr at 37°and subsequently co-incubated with live FITC-labelled S. aureus at a ratio of 1 : 10 (cells : S. aureus) for 30 min at 37°. During co-incubation of leucocytes and bacteria, PAR 2 -cAP and IFN-c were applied in the same order and the same concentrations as during the pre-treatment of leucocytes by these stimuli. The efficacy of phagocytosis was determined by FACS analysis as described previously. M) alone or in combination with IFN-c (100 ng/ml) was applied for 28 hr (the maximum effect of the stimuli at MCP-1 release was noticed at this timepoint). After treatment, cell culture supernatants were collected and used to measure MCP-1 concentration by human CCL2/MCP-1 (R&D Systems) ELISA kit.
Statistical analysis
Results are expressed as mean ± SEM. At least three independent experiments were performed. Statistical evaluation was performed by paired two-tailed Student's t-tests. Significance was set at P < 0Á05.
Results
PAR 2 agonist alone enhances the phagocytic activity of human neutrophils and monocytes, but does not affect IFN-c-stimulated phagocytosis Neutrophils and macrophages from PAR 2 -deficient mice have been shown to display a significantly reduced phagocytic efficiency of Pseudomonas aeruginosa compared with cells from wild-type animals. 24 However, the ability of PAR 2 agonist to enhance the phagocytic activity of human neutrophils and monocytes and to affect IFN-cstimulated phagocytosis has yet to be evaluated. To investigate whether PAR 2 agonist might potentially enhance the IFN-c-induced phagocytosis we first carried out the phagocytosis assay with FITC-conjugated killed S. aureus. The treatment of human neutrophils with either PAR 2 -cAP (1 · 10 )4 M) or IFN-c (100 ng/ml) alone led to a similar enhancement of the mean fluorescence intensity (MFI) of human neutrophils (increased by around 40 ± 7% compared with untreated cells), indicating that the phagocytic activity of treated neutrophils increased (see supplementary material, Fig. S1 ). The combined action of PAR 2 -cAP and IFN-c did not enhance the phagocytic activity of neutrophils above that triggered by either agonist acting alone (combined treatment increased phagocytic activity by around 51 ± 12% as compared with untreated cells) (Fig. S1) . Treatment with the control peptide that cannot activate PAR 2 (PAR 2 -cRP: 1 · 10 )4 M) either alone or together with IFN-c did not affect the phagocytic activity of human neutrophils (Fig.  S1 ).
In our next experiments, we used live FITC-conjugated S. aureus (strain SH1000) to investigate the effect of PAR 2 -cAP alone or together with IFN-c on the phagocytic activity of human monocytes and neutrophils against viable bacteria. We found that PAR 2 -cAP (1 · 10 )4 M) or IFN-c (100 ng/ml) alone enhanced phagocytic activity ( Fig. 1a-d ; a,b for neutrophils and c,d for monocytes). Although IFN-c already appeared to stimulate phagocytic activity of monocytes at a concentration of 10 ng/ml, these effects were not statistically significant (Fig. 1c,d ).
Interferon-c at a higher concentration (100 ng/ml) also enhanced phagocytic activity of human monocytes and neutrophils. The effects of IFN-c at a concentration of 100 ng/ml reached statistical significance (Fig. 1a-d) . Stimulation with IFN-c increased the number of FITCpositive human monocytes (49 ± 13% of change compared with untreated cells) and FITC-positive human neutrophils (41 ± 7% of change compared with untreated cells). The MFI also increased in IFN-c-treated human monocytes (increased by 53 ± 14%) and neutrophils (increased by 80 ± 18%) compared with untreated controls. PAR 2 -cAP led to an increase in the amount of FITC-positive monocytes (increased by 35 ± 7%) and FITC-positive neutrophils (increased by 24 ± 4%) compared with untreated samples. The MFI also increased in monocytes treated with PAR 2 -cAP (increased by 38 ± 8%) and in neutrophils (increased by 38 ± 4%) compared with untreated control samples. The combined action of PAR 2 -cAP and IFN-c using the same concentrations did not enhance the phagocytic activity of neutrophils or monocytes beyond that triggered by either agonist acting alone (Fig. 1a-d) .
Interferon-c is a well-known endogenous modulator of phagocytic bacteria killing and secretory activity of human neutrophils and human monocytes. 25, 26 As an exogenous activator, LPS also affects phagocytic activity of both cell types. We wondered whether PAR 2 -cAP stimulation might interfere with LPS-modulated phagocytic activity of human neutrophils and monocytes. However, PAR 2 -cAP stimulation of human neutrophils as well as monocytes did not enhance the LPS-induced phagocytic activity against S. aureus (see supplementary material, Fig.  S2 ). Hence, despite the fact that PAR 2 -cAP alone up-regulates the phagocytic activity of human neutrophils and monocytes against S. aureus, this agonist failed to enhance IFN-c-induced and LPS-induced phagocytic activity.
PAR 2 agonist alone increases bacterial killing by human neutrophils, but does not enhance IFN-c-stimulated bacterial killing
We next investigated whether treatment of isolated human neutrophils with PAR 2 -cAP alone or in combination with IFN-c affects the bactericidal activity of these phagocytes. In accordance with biosafety limitations, we used live E. coli bacteria in our experiments to estimate neutrophil killing activity. Human neutrophils were pre-treated for 2 hr with PAR 2 -cAP or IFN-c either alone or in combination. Either PAR 2 -cAP (1 · 10 )4 M) or IFN-c (100 ng/ml) alone had a similar effect on bacteria killing by human neutrophils (killing efficacy increased by 62 ± 16% after PAR 2 -cAP and by 72 ± 10% after IFN-c) (Fig. 2) . The PAR 2 agonist and IFN-c in combination were not more effective in stimulating bacteria killing activity against E. coli than either was alone (Fig. 2) .
Stimulation with IFN-c enhances PAR 2 -cAP-induced release of MCP-1 by human neutrophils and monocytes
It is known that MCP-1 facilitates monocyte recruitment to the site of bacterial infection and enhances the engulfment of apoptotic neutrophils (efferocytosis), thereby helping to resolve acute inflammation. 11, 14 Moreover, neutrophils may be a source of MCP-1 in time-delayed responses. 13 We therefore studied the changes of MCP-1 secretion by human neutrophils and monocytes to reveal the effects of the PAR 2 agonist acting either alone or in combination with IFN-c. For this experiment, neutrophils and monocytes were treated with PAR 2 -cAP (1 · 10
M), or IFN-c (100 ng/ml) either alone or in combination. We found that PAR 2 -cAP alone did not lead to a notable change in MCP-1 secretion by human neutrophils after 20 hr of treatment; the level of secreted MCP-1 was still slightly below the threshold level of the ELISA (Fig. 3a) . However, treatment of human neutrophils with PAR 2 -cAP for 28 hr resulted in a significant increase of MCP-1 secretion by these cells (MCP-1 level in PAR 2 -cAP stimulated samples was 36 ± 4 pg/ml, but was undetectable in unstimulated control samples) (Fig. 3b) . Treatment of neutrophils with IFN-c alone did not affect MCP-1 secretion at the 20 and 28 hr timepoints. The level of secreted MCP-1 was below the threshold level of the ELISA at 20 hr and at 28 hr (Fig. 3a,b) . Surprisingly, the co-application of IFN-c with PAR 2 -cAP enhanced the effect of the PAR 2 agonist on MCP-1 secretion 20 hr after stimulation (Fig. 3a) . This effect was statistically significant even at 20 hr after stimulation (Fig. 3a) . However, this effect was even more prominent at 28 hr (MCP-1 level was 284 ± 37 pg/ml versus 36 ± 4 pg/ml in samples treated by PAR 2 -cAP alone) (Fig. 3b) . Treatment with the PAR 2 -inactive control peptide PAR 2 -cRP (1 · 10 )4 M) alone or together with IFN-c did not affect MCP-1 secretion by human neutrophils (Fig. 3a,b) .
We also investigated whether treatment of human monocytes with PAR 2 -cAP alone or in combination with IFN-c affects MCP-1 secretion. Here, we measured the level of secreted MCP-1 at 28 hr after stimulation of human monocytes with PAR 2 -cAP or IFN-c alone or in combination. We found that stimulation of human neutrophils for 28 hr with PAR 2 -cAP alone, but especially in combination with IFN-c, led to a statistically significant increase of MCP-1 secretion. We wondered whether monocytes would also be responsive to such stimulation at this time-point. Indeed, PAR 2 -cAP enhanced MCP-1 secretion by human monocytes (Fig. 3c) . The level of MCP-1 in untreated monocytes was 71 ± 10 pg/ml, but it was 271 ± 60 pg/ml in monocytes treated with PAR 2 -cAP. When monocytes were stimulated with IFN-c alone m activating peptide (cAP), 100 ng/ml IFN-c, or both, for 2 hr before incubation with living Escherichia coli. The same stimuli were further used during incubation of neutrophils and bacteria. The number of bacterial colonies formed after co-incubation with untreated neutrophils was considered to be 100%. The results are presented as an average number of bacterial colonies formed after co-incubation with stimulated neutrophils ± SEM (results are expressed as percentages). Student's t-test versus controls: **P < 0Á01. Eight independent experiments were performed. Student's t-test versus controls: **P < 0Á01; ***P < 0Á005. Five independent experiments were performed for human neutrophils and four independent experiments for human monocytes.
MCP-1 secretion was not notably affected (Fig. 3c) . However, when IFN-c and PAR 2 -cAP were used together, MCP-1 secretion was enhanced significantly (1686 ± 335 pg/ml versus 271 ± 60 pg/ml in samples treated by PAR 2 -cAP alone) (Fig. 3c) .
The inhibition of PI3 kinase and PKCd abolishes the enhancement of MCP-1 secretion after co-stimulation of human neutrophils with IFN-c and PAR 2 -cAP
We next investigated which intracellular signalling molecules were involved in the effects of PAR 2 agonist on MCP-1 secretion by human neutrophils, when this agonist was applied alone or in combination with IFN-c. In these experiments, we investigated the effects of the inhibitors of different intracellular signalling molecules: rottlerin (inhibits PKCd), LY294002 (inhibits PI3 kinase), SB203580 (inhibits p38 kinase), and JAK inhibitor I pyridone 6 (inhibits JAKs). Experiments were performed with neutrophils treated for 28 hr with PAR 2 agonist alone (PAR 2 -cAP 1 · 10
M) or in combination with IFN-c (100 ng/ ml), because the maximum effect on the MCP-1 secretion was revealed at that time-point. We found that rottlerin and LY294002 each completely abolished the effect of co-application of PAR 2 -cAP and IFN-c on MCP-1 release by human neutrophils (Fig. 4a) . These results indicate the crucial role of PI3 kinase and PKCd in enhancing MCP-1 secretion after co-stimulation of human neutrophils with PAR 2 -cAP and IFN-c. In addition, treating neutrophils with either pyridine 6 or SB203580 only weakened the effect of PAR 2 -cAP and IFN-c on MCP-1 secretion, which shows that p38 kinase and JAKs are involved in the combined action of both agonists (Fig. 4a) .
We also examined which intracellular signalling molecules are involved in the enhanced secretion of MCP-1 by human neutrophils after treatment with PAR 2 -cAP alone (Fig. 4b) . For these experiments, rottlerin, LY294002, SB203580 and pyridine 6 were used to check whether PI3 kinase, PKCd, p38 kinase and JAKs were involved in the solo effect of PAR 2 agonist on MCP-1 secretion by neutrophils. Rottlerin, LY294002 and SB203580 abolished PAR 2 -cAP-induced MCP-1 secretion (Fig. 4b) , indicating a crucial role of PI3 kinase, p38 kinase and PKCd on the effect of PAR 2 stimulation. However, pyridine 6 did not significantly affect the changes in MCP-1 release, indicating that JAKs do not participate in the effect induced by PAR 2 agonist alone (Fig. 4b) .
The inhibition of PI3 kinase and JAKs in human monocytes reduces the enhancement of MCP-1 secretion caused by co-stimulation with PAR 2 -cAP and IFN-c
We also investigated whether rottlerin (inhibits PKCd), LY294002 (inhibits PI3 kinase), SB203580 (inhibits p38 kinase), and JAK inhibitor I pyridone 6 (inhibits JAKs) affected the induction of MCP-1 secretion after stimulation of human monocytes with PAR 2 -cAP and IFN-c (Fig. 5a ). Experiments were performed with monocytes treated with PAR 2 -cAP together with IFN-c for 28 hr. We found that LY294002 and JAK inhibitor I pyridone 6 each reduced the effect of co-stimulation with PAR 2 -cAP and IFN-c on the MCP-1 secretion by human monocytes (MCP-1 level was 1686 ± 335 pg/ml in samples treated with both PAR 2 -cAP and IFN-c, 333 ± 140 pg/ml in samples treated with LY294002, and 352 ± 121 pg/ml in samples treated with JAK inhibitor) (Fig. 5a ). SB203580 had Results are presented as the average values of MCP-1 secretion by unstimulated, as well as by stimulated neutrophils in pg/ml ± SEM. Student's pairwise t-test: *P < 0Á05, **P < 0Á01, ***P < 0Á005. Four independent experiments were performed.
no effect on MCP-1 secretion by human monocytes (Fig. 5a) . Surprisingly, rottlerin enhanced the effect of co-stimulation with PAR 2 -cAP and IFN-c on MCP-1 secretion by monocytes (Fig. 5a ) and also enhanced PAR 2 -cAP-induced MCP-1 release when PAR 2 agonist was used alone (Fig. 5b) . However, rottlerin did not affect MCP-1 levels in IFN-c stimulated cells (data not shown).
We were also interested in whether rottlerin alone might affect MCP-1 secretion by human monocytes and found that it did increase secretion (Fig. 5c ). SB203580 and JAK inhibitor each did not affect MCP-1 secretion triggered by PAR 2 -cAP (Fig. 5b) . LY294002 slightly reduced the effect of PAR 2 -cAP stimulation on MCP-1 secretion by human monocytes (the level of MCP-1 secretion after PAR 2 -cAP application was 271 ± 60 pg/ml and if LY294002 was also added, the level of MCP-1 was 154 ± 72 pg/ml) (Fig. 5b) . In all cases, treatment of monocytes with DMSO did not affect MCP-1 secretion (Fig. 5a-c) .
Discussion
The most important finding of our study is that PAR 2 activation enhances phagocytic activity against Gram-positive (S. aureus) bacteria and the killing of Gramnegative (E. coli) bacteria by human leucocytes. The magnitude of the bactericidal effect induced by PAR 2 agonist was similar to that induced by IFN-c (Figs 1 and 2 ; see supplementary material, Fig. S1 ). Since PAR 2 agonist can synergize with IFN-c in enhancing anti-viral responses, 8, 9 we investigated whether co-application of PAR 2 -cAP and IFN-c led to stronger anti-bacterial responses of innate immune cells, but found that the response was no greater than when each compound was used alone (Figs 1 and 2 ; Fig. S1 ). In addition, PAR 2 agonist stimulation also failed to enhance LPS-stimulated phagocytic activity of neutrophils and monocytes (see supplementary material, Fig. S2 ). Hence, PAR 2 stimulation might trigger additional mechanisms that enhance the phagocytic activity of innate immune cells, and these mechanisms do not synergize with IFN-c or LPS-triggered ones. Unfortunately, it remains problematic to investigate whether the classic PAR 2 activators trypsin and tryptase can affect phagocytic and bacteriakilling activity of human innate immune cells. Trypsin and tryptase are known to induce PAR-independent effects. 5, 6 These effects could confound the data obtained using these enzymes as PAR 2 agonists.
Cytokines and chemokines influence the recruitment of phagocytes to the site of pathogen infection. The PAR 2 agonists reportedly affect the secretion of IFN-inducible protein-10, IL-8, IL-6 and IL-1b by human neutrophils, monocytes and endothelial cells. 8, 10, 27 Among chemokines, MCP-1 appears to play a distinct role linking neutrophils and monocytes during time-delayed inflammatory response, and helping to resolve inflammation via activation of efferocytosis.
14 In addition, IFN-c reportedly enhances time-delayed MCP-1 secretion by human neutrophils. 13 In our study, we investigated whether PAR 2 activation interferes or synergizes with IFN-c-enhanced MCP-1 secretion. We found that MCP-1 secretion by human neutrophils and monocytes was enhanced 28 hr after stimulation with PAR 2 -cAP (Fig. 3) . Moreover, the treatment of human neutrophils and monocytes with IFN-c together with PAR 2 -cAP resulted in a synergistic action of these agents, and so enhanced secretion of MCP-1 by innate immune cells (Fig. 3) . These findings indicate that the combination of PAR 2 -cAP and IFN-c is apparently effective at enhancing secretion of MCP-1 by human neutrophils and monocytes.
In our study, we were interested in which intracellular signalling molecules were involved in the synergetic action of PAR 2 -cAP and IFN-c on MCP-1 secretion by human neutrophils and monocytes. Several signalling molecules are known to be involved in the regulation of MCP-1 secretion. For example, a serine protease plasmin induces MCP-1 expression in human monocytes via activation of p38 kinase and JAK/signal transducer and activator of transcription (STAT) pathways. 28 Inhibitors of PI3 kinase attenuate IFN-c-induced expression of MCP-1 in macrophages. 29 Moreover, IFN-c-induced activation of PI3 kinase results in down-stream activation of PKCd. 30 Conversely, PAR 2 induces some effects via signalling cascades involving PI3 kinase and PKCd. 31 Altogether, these facts led us to hypothesize that p38 kinase, PI3 kinase, PKCd and JAKs were involved in the synergistic effect of PAR 2 agonist and IFN-c on MCP-1 secretion by human monocytes and neutrophils. Indeed, our experiments with inhibitors of these signalling molecules indicate that they all participate in synergistic effects of PAR 2 -cAP and IFNc on MCP-1 secretion by human neutrophils (Fig. 4a) . Our results show that the enhanced effect of combined PAR 2 -cAP and IFN-c treatment on MCP-1 secretion by human neutrophils appears to be associated with the signalling pathway JAK-PI3K-PKCd (Fig. 6a) . Possibly, STAT1 could be the next participant in this pathway in neutrophils. Interferon-c is known to activate the PI3K-PKCd axis, and activated PKCd, in turn, affects STAT1 phosphorylation. 30 The PKCd is involved in a dual mechanism by which it participates in regulating IFN-dependent responses: (i) via STAT1 phosphorylation and (ii) via p38 mitogen-activated protein (MAP) kinase activation. 32 The results of our study strongly suggest that PKCd is the upstream activator of p38 MAP kinase during combined action of PAR 2 -cAP and IFN-c on MCP-1 secretion by human neutrophils. We found that PKCd inhibition abolished the effect of co-application of PAR 2 -cAP and IFN-c on MCP-1 secretion, but that p38 MAP kinase inhibitor just weakened MCP-1 secretion by human neutrophils (Fig. 4a) . In addition, we found that the PI3K-PKCd axis plays a crucial role for MCP-1 secretion by human neutrophils stimulated with PAR 2 -cAP alone (Fig. 4b) .
However, our study shows that human monocytes demonstrate not only similarities, but also differences, in the set of signalling molecules involved in the synergistic effect of PAR 2 -cAP and IFN-c on MCP-1 secretion (Fig. 6b) . The inhibition of PI3K and JAKs reduced, but did not abolish, the enhanced MCP-1 secretion, which was induced after monocytes were treated with PAR 2 -cAP together with IFN-c (Fig. 5a ). This reduced level of secreted MCP-1 was similar to the level reached after monocytes were stimulated with PAR 2 -cAP alone (Fig. 5a,b) . These data indicate that PAR 2 -cAP effects on MCP-1 secretion by human monocytes are mediated not only via a signalling pathway involving PI3K activation, but also via another pathway (Fig. 6b) . Surprisingly, the PKCd inhibitor rottlerin enhanced the effect of PAR 2 -cAP and IFN-c on MCP-1 release by monocytes (Fig. 5a ). Rottlerin also synergized with PAR 2 -cAP in its action on MCP-1 secretion (Fig. 5b) . Moreover, rottlerin, when applied alone, enhanced MCP-1 secretion by human monocytes (Fig. 5c) . Treatment with the p38 inhibitor SB203580 did not influence the increased MCP-1 secretion caused by either PAR 2 -cAP stimulation or combined application of PAR 2 -cAP and IFN-c (Fig. 5a,b) . The levels of secreted MCP-1 after IFN-c stimulation were below the threshold in the neutrophil samples and could therefore not be determined (Fig. 3a,b) . The treatment of human monocytes with IFN-c yielded no significant changes in MCP-1 levels (Fig. 3c) . Hence, the effects of the inhibitors of signalling molecules at MCP-1 release were not studied after IFN-c stimulation of human monocytes and neutrophils. Altogether, the results of our experiments allowed us to suggest a possible scheme of signalling events involved in the enhancement of MCP-1 secretion triggered after combined stimulation of human neutrophils and monocytes with PAR 2 -cAP and IFN-c (Fig. 6a,b) . In summary, our study demonstrates that PAR 2 agonist acting alone can enhance a bactericidal response of human neutrophils and monocytes in vitro. However, PAR 2 agonist is unable to synergize with IFN-c in the enhancement of the bactericidal response. On the other hand, PAR 2 agonist and IFN-c do synergize to increase MCP-1 secretion by human neutrophils and monocytes during the late phase (after 24 hr) of the inflammatory response. This synergistic action of PAR 2 agonist and IFN-c on MCP-1 release apparently involves the activation of PI3 kinase and JAKs in neutrophils and monocytes.
